Revenue Update on Derma Sciences Inc(NASDAQ:DSCI)

Derma Sciences Inc(NASDAQ:DSCI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Company reported revenue of $22.21M. Analysts estimated a revenue of $22.40M. Earnings per share were $-0.07. Analysts had estimated an EPS of $-0.08.

Derma Sciences Inc (DSCI) shares turned negative on Wednesdays trading session with the shares closing down -0.01 points or -0.20% at a volume of 15,999. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.218. The peak price level was also seen at $5.218 while the days lowest was $4.77. Finally the shares closed at $4.91. The 52-week high of the shares is $6.85 while the 52-week low is $2.85. According to the latest information available, the market cap of the company is $139 M.

Several Insider Transactions has been reported to the SEC. On Aug 18, 2015, Srini Conjeevaram (director) purchased 1,100 shares at $6.50 per share price.Also, On Aug 14, 2015, Bruce F Wesson (director) purchased 10,000 shares at $6.58 per share price.On Aug 14, 2015, Robert C Cole (officer ) purchased 5,000 shares at $6.73 per share price, according to the Form-4 filing with the securities and exchange commission.

Derma Sciences Inc. (Derma Sciences) is a tissue regeneration company which is engaged in the research and management of acute and chronic wounds and burns. The Company operates through three segments: pharmaceutical wound care advanced wound care and traditional wound care products. Pharmaceutical wound care products consist of DSC127 a product for the treatment of a variety of dermal applications including diabetic foot ulcers and scar prevention. DSC127 for diabetic foot ulcers is in Phase III of clinical development and in pre-clinical stage of scar prevention. Advanced wound care products consist of differentiated dressings bandages and ointments for wound healing and/or prevent infection including MEDIHONEY TCC-EZ AMNIOEXCEL and AMNIOMATRIX XTRASORB and BIOGUARD. Traditional wound care products consist of commodity related dressings ointments gauze bandages adhesive bandages wound closer strips catheter fasteners and skin care products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Derma Sciences Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Derma Sciences Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.